Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 32 (6), 1246-57

Phase I Dose-Escalation Study of SGN-75 in Patients With CD70-positive Relapsed/Refractory non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma

Affiliations
Clinical Trial

Phase I Dose-Escalation Study of SGN-75 in Patients With CD70-positive Relapsed/Refractory non-Hodgkin Lymphoma or Metastatic Renal Cell Carcinoma

Nizar M Tannir et al. Invest New Drugs.

Abstract

Purpose: This first-in-human study evaluated the CD70-targeted antibody-drug conjugate SGN-75 in patients with relapsed or refractory CD70-positive non-Hodgkin lymphoma (NHL) or metastatic renal cell carcinoma (RCC). Methods SGN-75 was administered intravenously to 58 patients (39 RCC, 19 NHL) every 3 weeks (Q3Wk; doses escalated from 0.3 to 4.5 mg/kg) or on Days 1, 8, and 15 of 28-day cycles (weekly; doses of 0.3 or 0.6 mg/kg). Dose-limiting toxicities were evaluated during Cycle 1; treatment response was monitored every 2 cycles.

Results: The maximum tolerated dose of SGN-75 in RCC patients was 3 mg/kg Q3Wk. Due to toxicity concerns (idiopathic thrombocytopenic purpura in 2 NHL patients treated weekly), dose escalation in the weekly schedule was terminated; no regimen was recommended for NHL patients. The most common adverse events reported in patients treated Q3Wk (N = 47) were fatigue (40%), dry eye (32%), nausea (30%), and thrombocytopenia (26%). The nadir for thrombocytopenia typically occurred during Cycle 1. Ocular adverse events (e.g., corneal epitheliopathy, dry eye) were reported for 57% of patients treated Q3Wk and were generally reversible. Antitumor activity in patients treated Q3Wk included 1 complete response, 2 partial responses, and 20 stable disease. SGN-75 exposures were approximately dose proportional, with a mean terminal half-life of 10 days. Substantial depletions of CD70-positive peripheral blood lymphocytes were observed after SGN-75 treatment.

Conclusions: Modest single-agent activity and generally manageable adverse events were observed in heavily pretreated RCC and NHL patients. Administration Q3Wk was better tolerated than weekly dosing. Targeted ablation of CD70-positive lymphocytes was demonstrated.

Trial registration: ClinicalTrials.gov NCT01015911.

Similar articles

See all similar articles

Cited by 24 articles

See all "Cited by" articles

References

    1. Curr Opin Immunol. 2005 Jun;17(3):275-81 - PubMed
    1. J Clin Oncol. 2007 Feb 10;25(5):579-86 - PubMed
    1. Blood. 2008 Dec 1;112(12):4683-9 - PubMed
    1. Clin Cancer Res. 2008 Dec 1;14(23):7763-72 - PubMed
    1. Mol Immunol. 1995 Jul;32(10):761-72 - PubMed

Publication types

MeSH terms

Associated data

Feedback